ライフサイエンスコーパス: safety concern

1 ed venous thromboembolism is a major patient safety concern.

2 n aniline, a structural motif of prospective safety concern.

3 es in animal-derived foods are a global food safety concern.

4 dditional studies are needed to address this safety concern.

5 rations in liver or kidney function or other safety concern.

6 tly excised using Cre/Lox system for vaccine safety concern.

7 tional studies have addressed this important safety concern.

8 interactions translates into a considerable safety concern.

9 There was no safety concern.

10 eripheral artery disease, but mortality is a safety concern.

11 as interferon-stimulated raised considerable safety concern.

12 ugh off-target editing remains a significant safety concern.

13 ADRs presented in BW, which is of most drug safety concern.

14 nted or unexpected events, which are a major safety concern.

15 hat utilizes standing dead trees removed for safety concerns.

16 onsibility for self-management, often due to safety concerns.

17 BCG2 inhibition at the BBB may be limited by safety concerns.

18 ystems with poor cycling stability, and real safety concerns.

19 onary hypertension patients, with no hepatic safety concerns.

20 monary tuberculosis disease, without evident safety concerns.

21 o dissect underlying mechanisms, and explore safety concerns.

22 ly reporting of the study results because of safety concerns.

23 eatment of ulcerative colitis, but there are safety concerns.

24 ssociated with patient compliance issues and safety concerns.

25 orticoids, have limited efficacy and present safety concerns.

26 ability to address individual end points or safety concerns.

27 There were no safety concerns.

28 nal liquid electrolytes can pose significant safety concerns.

29 continued abruptly or inappropriately due to safety concerns.

30 nce from communities, and prolonged regional safety concerns.

31 R was well tolerated by all patients without safety concerns.

32 motor outcomes and corticosteroid-associated safety concerns.

33 s in previous MC1R ligand development raises safety concerns.

34 nt 2G-TKI yields promising TFR rates without safety concerns.

35 es for individual drugs, without significant safety concerns.

36 een associated with RBC transfusion, raising safety concerns.

37 industrial chemical with health and product safety concerns.

38 o lead to undesirable side effects and major safety concerns.

39 oulombic efficiency, short lifespan and even safety concerns.

40 such as fingolimod have been weighed down by safety concerns.

41 patients after a safety analysis because of safety concerns.

42 ically well-defined heterointerfaces without safety concerns.

43 the first trimester of pregnancy because of safety concerns.

44 the rate of uncommon or rare side effects or safety concerns.

45 ts with multiple sclerosis but has potential safety concerns.

46 ium plating on the graphite surface, raising safety concerns.

47 PSPs than with a known change in efficacy or safety concerns.

48 a dose-dependent manner, without significant safety concerns.

49 3AV induced high SPR and there were no safety concerns.

50 There were no vaccine- or CHMI-related safety concerns.

51 People appear to walk for transport despite safety concerns.

52 .S. market for cosmetic use in 1992 owing to safety concerns.

53 Both drugs were well tolerated with no safety concerns.

54 nd those widely used in livestock have major safety concerns.

55 tal HIV infection; a dose that has not shown safety concerns.

56 potential therapy for GBM is limited due to safety concerns.

57 data and safety monitoring board because of safety concerns.

58 e activities after flushing because of water safety concerns.

59 study, with comparable efficacy and no late safety concerns.

60 ficiency, lack of cell-specific targeting or safety concerns.

61 hich time recruitment was suspended owing to safety concerns.

62 vention, but cautious use is essential given safety concerns.

63 retention in patients' bodies, which causes safety concerns.

64 argeable batteries is associated with severe safety concerns.

65 ed for children under 2 or asthmatics due to safety concerns.

66 anti-inflammatory drugs (NSAIDs) could pose safety concerns.

67 We did not identify any new safety concerns.

68 ucceeded owing to the lack of efficacy or to safety concerns.

69 t, ivacaftor was well tolerated, with no new safety concerns.

70 latory frameworks, clinical experiences, and safety concerns.

71 Treatments were well tolerated with no safety concerns.

72 immune responses without raising significant safety concerns.

73 is variably used because of invasiveness and safety concerns.

74 ight lead to higher efficacy but also to new safety concerns.

75 nt in progression-free survival, with no new safety concerns.

76 t commercial vaccines without the associated safety concerns.

77 s with transplant-eligible NDMM, with no new safety concerns.

78 istinct functionalities and address separate safety concerns.

79 but several have been discontinued owing to safety concerns.

80 l acuity, and intraocular pressure raised no safety concerns.

81 lesion revascularization, without thrombotic safety concerns.

82 est drives, 16 (8.5%) were terminated due to safety concerns.

83 ty with respect to the primary end point and safety concerns.

84 remains one of the world's public health and safety concerns.

85 ansplantation (SOT) patients has theoretical safety concerns.

86 Eculizumab was well tolerated with no new safety concerns.

87 does not support any of the reviewed vaccine safety concerns.

88 Tolerability was similar to placebo, with no safety concerns.

89 meat is subject to regulations, due to food safety concerns.

90 n with very limited efficacy and significant safety concerns.

91 ds might be inadequate or cause considerable safety concerns.

92 municate the value of the study, and address safety concerns.

93 A composite of (1) withdrawals due to safety concerns, (2) FDA issuance of incremental boxed w

94 255 incidents, which were classified as 132 safety concerns (51.8%), 102 nonsafety-related quality c

95 literature suggest that there are three main safety concerns: (a) to prevent biological or neural dam

96 lendar year (before/after February 2008 when safety concerns about intensive glucose control were rep

97 erm ovarian function and pregnancies and the safety concerns about the potential negative interaction

98 n and the resulting immunodeficiency prompts safety concerns about their use.

99 Several analyses raised safety concerns about vitamin D(3) doses of 1000 IU/d or

100 We did not identify any safety concerns after PPV in our patients with dense non

101 s at the higher doses, there were no notable safety concerns after subretinal delivery of an adeno-as

102 potentially affected represents an important safety concern and requires an immediate change in pract

103 data and safety monitoring board because of safety concerns and a low likelihood of a significant di

104 foundly affected psychiatric research due to safety concerns and containment efforts.

105 Treatment with desmoteplase did not cause safety concerns and did not improve functional outcome w

106 We identified no new safety concerns and few patients discontinued treatment

107 imited in daily clinical practice because of safety concerns and lack of physiological benefit.

108 and mossy metal deposits, leading to serious safety concerns and low Coulombic efficiency during char

109 bility of medications, and also presents new safety concerns and monitoring requirements with which p

110 We found no clinically relevant safety concerns and no serious adverse events associated

111 ocols (i.e. empirical dosing, driven by both safety concerns and practical aspects).

112 To mitigate safety concerns and simplify reaction execution, an HF-f

113 ological disorders but have also highlighted safety concerns and technology gaps.

114 ability and efficacy of outcomes, as well as safety concerns and the cost-to-benefit ratio were also

115 n has been reported in adults, there were no safety concerns and the overall bone and renal safety pr

116 Early trial termination for safety concerns and the possibility that the study was u

117 The interventions did not raise any safety concerns and there were no differences between gr

118 There were no new or long-term safety concerns and tolerability was similar across grou

119 h approach has potential advantages but also safety concerns and unresolved questions.

120 dapivirine ring was not associated with any safety concerns and was associated with a rate of acquis

121 olecule agents, pharmacokinetic limitations, safety concerns, and a complex regulatory environment.

122 development to improve performance, address safety concerns, and fulfil regulatory obligations is re

123 vailable efficacy and safety data, potential safety concerns, and long-term effect in children with a

124 Therapies are limited by efficacy, safety concerns, and multiple daily dosing.

125 of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole

126 of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole

127 There were no unexpected safety concerns, and the results support the continued d

128 use, parental perceptions that vaccines pose safety concerns are affecting vaccination rates, particu

129 An examination of how potential safety concerns are being navigated with compounds curre

130 ware interface to ensure that the three main safety concerns are closely monitored.

131 radiation levels to relatively high levels; safety concerns are largest for Bikini Island.

132 adoption in critical applications increases, safety concerns are resurfacing due to the inherent flam

133 No safety concerns arose during either microdialysis or sca

134 No new safety concerns arose over this extended follow-up.

135 herosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial e

136 evels of transgene expression or have raised safety concerns associated with extra-cardiac delivery.

137 Safety concerns associated with long-acting beta2-agonis

138 his single-device approach, coupling-related safety concerns associated with multiple conductor appro

139 This study further addresses safety concerns associated with the potential use of pre

140 ials have been concluded, showing no notable safety concerns associated with the use of phage.

141 To overcome the safety concerns associated with the whole-bacteria vacci

142 To address safety concerns associated with this vector, we develope

143 quired pressure ulcers are a serious patient safety concern, associated with poor patient outcomes an

144 The rationale for safety concerns at this field strength are discussed as

145 The rapid degradation of PTAs may address safety concerns but usually limits the photothermal stab

146 Gadolinium deposition has raised safety concerns, but it is unknown whether ferumoxytol a

147 xt, off-target edits in crops present no new safety concerns compared to other breeding practices.

148 ernative vaccine approach because of reduced safety concerns compared with live vaccines.

149 functional independence without evidence for safety concerns, compared to dMT, for AIS patients with

150 enuated HSV vaccines predicated on unfounded safety concerns currently limits their widespread accept

151 gh-energy-density batteries pose significant safety concerns due to high rates of heat generation.

152 -a]quinolines on multigram scale without any safety concerns due to the reaction's inherent exothermi

153 he treatments being evaluated have no or low safety concerns during pregnancy.

154 nsistently improved immune responses, and no safety concerns emerged in the context of IIV-HD revacci

155 Recent safety concerns enforced the search for alternative ultr

156 fects of the Cas9 nuclease represent a major safety concern for any therapeutic application.

157 The current food safety concern for food integrity demands the availabili

158 However, the SEM features raise safety concerns for capsular integrity after FLACS and w

159 First, current safety concerns for dolutegravir use in women of childbe

160 g dose, compared with the 50-mg dose, and no safety concerns for either dose or placebo.

161 ata, we did not detect any new or unexpected safety concerns for MMR vaccination in adults.

162 gies on the inherently toxic IL-2 has raised safety concerns for patients, justifying a search for al

163 etal batteries for energy storage and causes safety concerns for regular ambient-temperature Li metal

164 This causes serious safety concerns for state-of-the-art lithium-ion batteri

165 stem often require viral vectors, which pose safety concerns for therapeutic genome editing(1).

166 Current technologies raise safety concerns for unintended gene propagation.

167 There are also significant safety concerns for work with highly pathogenic IAV stra

168 pe as one strategy to potentially circumvent safety concerns from earlier derivatives such as in vitr

169 rect-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity.

170 However, several safety concerns have hindered the clinical development o

171 Nevertheless, safety concerns have limited its widespread use in human

172 reatments for SSSIs caused by MRSA; however, safety concerns have limited use of these agents.

173 ficile infection, but practical barriers and safety concerns have prevented its widespread use.

174 Persistent safety concerns have stalled the development of viable h

175 Beyond microbiological safety, concerns have been raised regarding contaminatio

176 nsity, wide temperature tolerance, and fewer safety-concerns, have been considered as a promising ene

177 rin and 152 placebo) because of futility and safety concerns identified by the Data Safety Monitoring

178 ailed to offer incremental benefit or raised safety concerns (ie, hypotension).

179 n of PERV-inactivated animals to address the safety concern in clinical xenotransplantation.

180 r-a-go-go-related gene]) channel are a major safety concern in drug development.

181 inetically favorable and it remains a severe safety concern in mass production.

182 To assess whether HBV-R is a safety concern in patients receiving HCV DAAs.

183 FG is a newly identified safety concern in patients receiving SGLT2 inhibitors.

184 s B virus reactivation is a newly identified safety concern in patients with HBV-HCV co-infection tre

185 Immunogenicity is a critical safety concern in the development of any protein therape

186 roclivity to avoid dominant animals, raising safety concerns in interspecies interactions.

187 Possible safety concerns in patients with a high liver tumor burd

188 l toxicological issues in healthy animals or safety concerns in spinal cord injury animals.

189 It impacts quality of life and creates safety concerns in the home, at work, and on the roads.

190 ssociated with any statistically significant safety concerns in the population studied.

191 Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, w

192 of CRISPR components and limits the possible safety concerns in vivo.

193 e greatest efficiency, they also raise major safety concerns including carcinogenesis and immunogenic

194 f CRISPR-Cas to biomedicine still faces many safety concerns, including off-target side effect, cell

195 However, the critical safety concern is the neurotropic nature conveyed by the

196 Modest efficacy, intolerance, and safety concerns limit current antiarrhythmic drugs.

197 ic inflammation, but lack of selectivity and safety concerns limit development.

198 Pathogen resistance and safety concerns limit oral antibiotic options for the tr

199 However, safety concerns limit the use of iodinated and gadoliniu

200 Before 2016, safety concerns limited metformin use in patients with k

201 into oblivion for several decades because of safety concerns, metallic Li is now ready for a revival,

202 Due to health and safety concerns, most wireless power transfer (WPT) sche

203 However, there has been safety concern of SPIONs with cirrhosis related to exces

204 ortunities to overcome these limitations and safety concerns of cardiac gene therapy.

205 These results highlight safety concerns of using low concentrations of DMSO as a

206 nd medication use without raising unexpected safety concerns, offering a minimally invasive surgical

207 serin was well tolerated with no significant safety concerns or worsening of motor function.

208 g to low absorption and bioavailability, and safety concerns owing to tight junction openings.

209 However, two safety concerns persist: endonuclease-associated adverse

210 Safety concerns pertaining towards fungal occurrence and

211 conducted original data analysis; considered safety concerns, potential benefits, research, and poten

212 n lead to regaining of its virulence creates safety concerns precluding many vaccines from clinical a

213 HZ/su was well-tolerated, with no safety concerns raised within 1 month post-dose 2.

214 Safety concerns regarding corneal thickness were taken i

215 However, safety concerns regarding target expression on healthy t

216 This work addresses some of the safety concerns regarding the potential use of predatory

217 f research in this arena, and discussions on safety concerns regarding the use of dental nanomaterial

218 ed effects of poor immune responsiveness and safety concerns regarding the use of live attenuated vac

219 hould be carefully characterized due to food safety concerns regarding this compound.

220 Given the safety concerns related to DTG during pregnancy, we asse

221 smission often exclude pregnant women due to safety concerns related to the drugs.

222 However, safety concerns related to the inability to control CAR-

223 Potential safety concerns relative to impaired cognitive function

224 Given that cardiovascular safety concerns remain the leading cause of drug attriti

225 ordings (r=0.63 [95% CI 0.53-0.79]), with no safety concerns reported.

226 approach, most notably in the SIV model, but safety concerns require the development of nonreplicatin

227 rging controls are used, alleviating a major safety concern (short-circuiting related to Li dendrite

228 ice, regulation of repackaged medication for safety concerns should also consider the evaluation of t

229 ic absorption greater than 0.5 ng/mL or with safety concerns should undergo nonclinical toxicology as

230 y clinical trials from poor exposure to drug safety concerns, such as drug-induced liver injury (DILI

231 ed with no unexpected or clinically relevant safety concerns, supporting further testing.

232 ion of permanently engineered T cells raises safety concerns that have hampered testing of this appro

233 and requires further refinement to alleviate safety concerns that include stroke.

234 monkey images for several reasons, including safety concerns that limited the light levels permissibl

235 therapeutics, despite modest efficacy, have safety concerns that underscore the need for effective p

236 optimised methodology was applied to assess safety concerning the content of PAHs in white and parbo

237 nerally well tolerated with no signals for a safety concern; there were no serious adverse events (AE

238 n-derived product, limited availability, and safety concerns, this treatment option has essentially b

239 The vaccine was well tolerated without safety concerns throughout the study.

240 ne was well tolerated and did not reveal any safety concerns throughout the study.

241 e human studies with aptamers have not shown safety concerns to date and have demonstrated effectiven

242 magnetic resonance imaging (MRI) because of safety concerns, unless the devices meet certain criteri

243 ate compounds with non-target effects and/or safety concerns until late in the drug developmental pro

244 reater antitumor activity without additional safety concerns versus ipilimumab.

245 mumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and

246 No safety concern was identified at doses up to 16 mg per k

247 Despite demonstrating no safety concerns, we conclude that patients with subarach

248 No safety concerns were associated with spirometry.

249 No safety concerns were identified after systemic administr

250 No safety concerns were identified after the ingestion of g

251 No safety concerns were identified at any of the dose level

252 No new safety concerns were identified for ceftazidime-avibacta

253 No additional safety concerns were identified for patients who switche

254 No safety concerns were identified in this short-term study

255 No new safety concerns were identified in this study.

256 of participants enrolled in these trials, no safety concerns were identified with passive immunizatio

257 No safety concerns were identified with the booster dose.

258 No new or long-term safety concerns were identified.

259 No major safety concerns were identified.

260 hen the vaccines were coadministered, and no safety concerns were identified.

261 l tolerated in this young population; no new safety concerns were identified.

262 d in previous RCTs, and no new or unexpected safety concerns were identified.

263 No overall safety concerns were identified.

264 more reactogenic than placebo, but no major safety concerns were identified.

265 No safety concerns were identified.

266 No vaccine safety concerns were identified.

267 No vaccine-associated safety concerns were identified.

268 m transient local and systemic reactions, no safety concerns were identified.

269 s in all participants, and no trial-limiting safety concerns were identified.

270 Eculizumab was well tolerated and no new safety concerns were identified.

271 No systemic safety concerns were identified; however, one participan

272 In this small study, no safety concerns were identified; however, transient feve

273 No safety concerns were noted during the 3-year follow-up.

274 INTERPRETATION: No new safety concerns were noted with eltrombopag and the tria

275 No major safety concerns were noted, with low rates of procedural

276 No safety concerns were noted.

277 lar efficacy and safety profiles, and no new safety concerns were noted.

278 erolimus remained well-tolerated, and no new safety concerns were noted.

279 No safety concerns were observed.

280 cine was well tolerated, and no dose-related safety concerns were observed.

281 , the vaccine regimens were tolerable and no safety concerns were observed.

282 No safety concerns were raised by the independent data moni

283 No safety concerns were raised in any age group.

284 r glycemic therapy deintensified, even after safety concerns were raised in the ACCORD trial.

285 No safety concerns were raised with IIV-HD revaccination.

286 No safety concerns were reported during the 28-day period a

287 Known safety concerns were validated, including elevated non-f

288 Cryomedium toxicity is a major safety concern when transplanting cryopreserved organs.

289 episodes from all six CTG trials revealed no safety concerns when compared with the RGT.

290 We found no evidence of any safety concerns when this vaccine was administered durin

291 positive health impact and resolve remaining safety concerns, wider roll-out could be recommended fro

292 nformatics approaches for PROTAC design, and safety concerns with a special focus on the development

293 We identified no safety concerns with either vaccine: seven (8%) of 91 pa

294 Safety concerns with erythropoietin analogues and intrav

295 owed durable responses and there were no new safety concerns with longer follow-up.

296 ese orthogonal safety switches address major safety concerns with pluripotent cell-derived therapies.

297 ause of growing antibacterial resistance and safety concerns with standard care.

298 There were no safety concerns with the intervention.

299 Conversely, there were no safety concerns with very low LDL-cholesterol concentrat

300 ough canned food consumption are an emerging safety concern worldwide.